Biomarker: BRAF

Dabrafenib (Tafinlar)

Combination Therapy, Targeted TherapyApproved for: NSCLCBiomarker: BRAF Dabrafenib (Tafinlar) is a FDA-approved Targeted Therapy/Combination Therapy for non-small cell lung cancer that has metastasized (NSCLC) with the biomarker BRAF. It is used with trametinib. Dabrafenib is used only in patients...
Read More
|
May 31, 2021
|
Treatment

Trametinib (Mekinist)

Combination Therapy, Targeted TherapyApproved for: NSCLCBiomarker: BRAF Trametinib (Mekinist) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has metastasized. It is used with dabrafenib. Trametinib is used only in patients whose cancer has a certain mutation...
Read More
|
May 31, 2021
|
Treatment